China De Xiao Quan Care Group Co., Ltd (CDXQ)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
China De Xiao Quan Care Group Co., Ltd (CDXQ) trades at $0.00 with AI Score 42/100 (Grade C). China De Xiao Quan Care Group Co. , Ltd. is a shell company with no significant operations, formerly involved in the medical marijuana sector. Market cap: $12,000, Sector: Financial services.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for CDXQ: CDXQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CDXQ against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CDXQ: the 1 perspectives are evenly split.
How is this calculated? →China De Xiao Quan Care Group Co., Ltd (CDXQ) Financial Services Profile
China De Xiao Quan Care Group Co., Ltd., based in New York, operates as a shell company, previously exploring medical marijuana technologies. With minimal operations and a small team, the company's current market position is tenuous, reflecting the high-risk nature of shell corporations within the financial services sector.
What Is the Investment Thesis for CDXQ?
Investing in China De Xiao Quan Care Group Co., Ltd. presents substantial risks due to its status as a shell company with no significant operations. The company's negative beta of -45.33 indicates an inverse correlation with the market, which is not necessarily indicative of stability. With a market cap of 12K and no dividend yield, the company offers no immediate return on investment. Any potential value would depend on speculative future activities, such as a reverse merger or acquisition. Investors may want to evaluate the high degree of uncertainty and the potential for complete loss of investment. The absence of revenue and active business operations makes traditional valuation methods inapplicable.
Based on FMP financials and quantitative analysis
CDXQ Key Highlights
- Market capitalization of 12K, reflecting the company's lack of significant operations.
- P/E ratio of 0.01, indicative of minimal earnings relative to its market capitalization.
- Beta of -45.33, suggesting an inverse correlation with the market.
- No dividend yield, indicating no current income for investors.
- Operates as a shell company with no significant ongoing business activities.
Who Are CDXQ's Competitors?
CDXQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NSH NavSight Holdings, Inc. | $9.93 | +3.01% | 69 | |
| LRGR Luminar Media Group, Inc. | $0.50 | +47.06% | $22.39M | 68 |
| LMAOU LMF Acquisition Opportunities, Inc. | $12.46 | +41.59% | 68 | |
| APXTW Apex Treasury Corporation | $0.37 | +5.11% | $1.96B | 66 |
| DGNR Dragoneer Growth Opportunities Corp. | $9.26 | +0.00% | $5.79B | 57 |
| KWM K Wave Media Ltd. | $0.15 | -2.40% | $10.04M | 57 |
| IOAC Innovative International Acquisition Corp. | $9.60 | -14.44% | $100.74M | 57 |
| ROCGU Roth CH Acquisition IV Co. | $10.29 | +2.90% | $57.15M | 57 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CDXQ's Key Strengths?
- Publicly listed status provides potential access to capital markets.
- Existing corporate structure facilitates potential restructuring or acquisition.
- Previous experience in the medical marijuana market provides some industry knowledge.
- Low operating costs due to minimal activity.
What Are CDXQ's Weaknesses?
- Lack of significant operations and revenue generation.
- Dependence on speculative future activities.
- Limited assets and resources.
- Negative market perception due to shell company status.
What Could Drive CDXQ Stock Higher?
- Potential announcement of a reverse merger or acquisition target.
- Possible restructuring and pivot to a new industry.
- Efforts to secure funding or investment for future ventures.
- Monitoring of regulatory changes in the medical marijuana market.
- Exploration of opportunities to monetize existing intellectual property.
What Are the Key Risks for CDXQ?
- Negative return on equity (-45.5%) — the business is not currently generating profit on shareholder capital.
- Regulatory scrutiny and delisting from the OTC market.
- Inability to attract suitable acquisition or merger partners.
- Failure to identify a viable new business model.
- Limited financial resources and dependence on external funding.
- Negative market perception due to shell company status.
What Are the Growth Opportunities for CDXQ?
- Potential acquisition or reverse merger: China De Xiao Quan Care Group Co., Ltd. could become an attractive target for a private company seeking to go public without undergoing the traditional IPO process. The timeline for such an event is highly uncertain, dependent on market conditions and the company's ability to attract a suitable partner. The market size for reverse mergers is estimated to be in the billions annually, but the success rate is variable.
- Restructuring and pivot to a new industry: The company could choose to redefine its business model and enter a new sector, leveraging its existing corporate structure. This would require significant capital investment and strategic planning. The timeline for such a transformation could be several years, and the success would depend on the company's ability to identify a viable market opportunity and execute effectively. The market size would depend on the chosen industry.
- Capitalizing on the medical marijuana market: Although the company previously abandoned its focus on medical marijuana, it could re-enter the market if regulations become more favorable and the industry matures. The global medical marijuana market is projected to reach $55 billion by 2026, presenting a substantial opportunity. However, competition is intense, and the company would need to develop a unique value proposition to succeed.
- Leveraging its listing for capital raising: As a publicly listed company, China De Xiao Quan Care Group Co., Ltd. has the potential to raise capital through equity offerings. This capital could be used to fund acquisitions, expand operations, or invest in new technologies. The amount of capital that can be raised depends on market conditions and investor confidence. The timeline for such an offering is uncertain, but it could provide the company with the resources needed to pursue growth opportunities.
- Monetizing its intellectual property: If China De Xiao Quan Care Group Co., Ltd. possesses any valuable intellectual property related to its previous activities in the medical marijuana market, it could seek to monetize these assets through licensing or sale. The value of such intellectual property is highly variable and depends on its uniqueness and market demand. The timeline for monetization is uncertain, but it could provide a source of revenue for the company.
What Opportunities Does CDXQ Have?
- Potential acquisition or reverse merger with a private company.
- Restructuring and pivot to a new industry.
- Re-entry into the medical marijuana market if regulations become more favorable.
- Monetization of any existing intellectual property.
What Threats Does CDXQ Face?
- Regulatory scrutiny and potential delisting.
- Inability to attract suitable acquisition or merger partners.
- Failure to identify a viable new business model.
- Loss of investor confidence and further decline in market capitalization.
What Are CDXQ's Competitive Advantages?
- As a shell company, China De Xiao Quan Care Group Co., Ltd. has no discernible competitive advantages.
- Its publicly listed status could provide a slight advantage in terms of access to capital markets, but this is not a significant moat.
- Any future competitive advantages will depend on the company's strategic direction and ability to execute.
What Does CDXQ Do?
China De Xiao Quan Care Group Co., Ltd., incorporated in 2012 and based in New York, currently lacks significant operational activities. Historically, the company focused on the development and commercialization of technologies within the medical marijuana market under its former name, Nhale, Inc. However, it has since ceased these activities. As of 2026, the company's primary function appears to be that of a shell corporation, with minimal assets or ongoing business operations. The company's transition from the medical marijuana sector to its current state reflects a significant shift in its strategic direction, leaving it without a clear market focus or revenue-generating activities. With a single employee and a market capitalization of 12K, the company's financial footprint is negligible. The company's future prospects are uncertain, dependent on potential restructuring or acquisition opportunities. The company's competitive positioning is non-existent, given its lack of active operations and market presence.
What Products and Services Does CDXQ Offer?
- Currently, China De Xiao Quan Care Group Co., Ltd. functions as a shell company.
- Previously, the company was involved in the development of medical marijuana technologies.
- The company seeks potential opportunities for restructuring or acquisition.
- It maintains a corporate structure as a publicly listed entity.
- The company explores options for future business ventures.
- It manages its limited assets and corporate obligations.
How Does CDXQ Make Money?
- Currently, the company does not have an active business model.
- Historically, the company aimed to generate revenue through the commercialization of medical marijuana technologies.
- Future revenue generation is contingent on potential restructuring or acquisition opportunities.
What Industry Does CDXQ Operate In?
China De Xiao Quan Care Group Co., Ltd. operates within the shell company segment of the financial services industry. Shell companies are often characterized by minimal operations and are sometimes used for reverse mergers or acquisitions. The industry is highly speculative and carries significant risks due to the lack of transparency and operational activity. Regulatory scrutiny is high, and the success of such entities depends heavily on future strategic decisions and market conditions. The competitive landscape is difficult to define, as shell companies are not directly competing in traditional markets but rather seeking opportunities for restructuring or acquisition.
Who Are CDXQ's Key Customers?
- Currently, the company does not have any active customers.
- Historically, the company targeted patients and consumers in the medical marijuana market.
- Future customer base will depend on the company's strategic direction.
China De Xiao Quan Care Group Co., Ltd (CDXQ) Valuation Context
Valued at 12K, CDXQ is classified as a micro-cap stock. Relative to its peer group, CDXQ's quantitative score of 42/100 is below the peer average of 65/100.
ROE -46%Key Financial Metrics
Return on equity for China De Xiao Quan Care Group Co., Ltd stands at -45.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. CDXQ trades at a trailing price-to-earnings ratio of 0.01, below the Financial Services sector average of ~18x. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 4/9Financial Health
China De Xiao Quan Care Group Co., Ltd's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
CDXQ Financials
Bull Case vs Bear Case
Bull Case
- Publicly listed status provides potential access to capital markets.
- Existing corporate structure facilitates potential restructuring or acquisition.
- Previous experience in the medical marijuana market provides some industry knowledge.
- Low operating costs due to minimal activity.
Bear Case
- Lack of significant operations and revenue generation.
- Dependence on speculative future activities.
- Limited assets and resources.
- Negative market perception due to shell company status.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
CDXQ Latest News
No recent news available for CDXQ.
CDXQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CDXQ.
Price Targets
Wall Street price target analysis for CDXQ.
CDXQ MoonshotScore
What does this score mean?
The MoonshotScore rates CDXQ's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Classification
Industry Shell CompaniesLeadership: Chunsheng Qin
Managing
Chunsheng Qin serves as the managing person for China De Xiao Quan Care Group Co., Ltd. Information regarding Mr. Qin's prior experience is not available. As the company currently operates with only one employee, Mr. Qin's role likely encompasses a broad range of administrative and strategic responsibilities. His background and expertise are critical to guiding the company through its current period of transition and exploring potential future opportunities.
Track Record: Given the company's current state as a shell corporation with minimal operations, it is difficult to assess Mr. Qin's track record. His primary focus has likely been on maintaining the company's corporate structure and exploring potential strategic options. Any future success will depend on his ability to identify and execute a viable business plan.
CDXQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that China De Xiao Quan Care Group Co., Ltd. may not meet the minimum financial standards or disclosure requirements of the higher tiers, such as OTCQX or OTCQB. Companies in this tier often have limited trading volume and liquidity, and may be subject to greater regulatory scrutiny. Investing in OTC Other stocks carries significant risks due to the lack of transparency and the potential for fraud or manipulation. Compared to NYSE/NASDAQ, OTC markets have far less stringent listing requirements.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited or no financial disclosure increases the risk of investing due to lack of transparency.
- Low trading volume and liquidity can lead to significant price volatility.
- Potential for fraud or manipulation is higher on the OTC Other tier.
- Company's status as a shell corporation increases the risk of complete loss of investment.
- Dependence on speculative future activities makes the investment highly uncertain.
- Verify the company's legal status and regulatory compliance.
- Obtain and review any available financial statements.
- Assess the company's management team and their track record.
- Evaluate the company's potential for future growth or restructuring.
- Understand the risks associated with investing in OTC Other stocks.
- Consult with a financial advisor before making any investment decisions.
- Check for any history of regulatory actions or legal issues.
- Publicly listed status provides some level of regulatory oversight.
- Company has been incorporated since 2012.
- Presence of a management team, however small.
- Company maintains a registered office in New York.
Common Questions About CDXQ (Financial Services)
What does China De Xiao Quan Care Group Co., Ltd do?
China De Xiao Quan Care Group Co., Ltd. currently operates as a shell company, meaning it has no significant ongoing business operations. Previously, it was involved in the development and commercialization of technologies related to the medical marijuana market. The company's current focus is on exploring potential opportunities for restructuring, acquisition, or a pivot to a new industry. Its value is primarily speculative, depending on its ability to secure a merger partner or develop a viable business plan. Investors should be aware of the high risks associated with investing in shell companies.
What do analysts say about CDXQ stock?
There is currently no analyst coverage for China De Xiao Quan Care Group Co., Ltd. due to its status as a shell company with minimal operations. Traditional valuation metrics are not applicable, and any investment decisions would be based on speculative future activities. Investors should conduct thorough due diligence and consider the high degree of uncertainty before investing. The company's financial performance and future prospects are highly dependent on its ability to execute a successful restructuring or acquisition.
What are the main risks for CDXQ?
The main risks for China De Xiao Quan Care Group Co., Ltd. include regulatory scrutiny, potential delisting from the OTC market, inability to attract suitable acquisition or merger partners, and failure to identify a viable new business model. The company's limited financial resources and dependence on external funding also pose significant risks. Additionally, the negative market perception associated with shell companies could further depress its market capitalization. Investors should be aware of the potential for complete loss of investment.
What are the key factors to evaluate for CDXQ?
China De Xiao Quan Care Group Co., Ltd (CDXQ) holds an AI score of 42/100 (low). Not financial advice.
How frequently does CDXQ data refresh on this page?
CDXQ prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CDXQ's recent stock price performance?
China De Xiao Quan Care Group Co., Ltd (CDXQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Publicly listed status provides potential access to capital markets. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CDXQ overvalued or undervalued right now?
Valuing China De Xiao Quan Care Group Co., Ltd (CDXQ) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CDXQ?
Before investing in China De Xiao Quan Care Group Co., Ltd (CDXQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is limited due to the company's status as a shell corporation.
- Financial data may not be reliable or up-to-date.
- Future prospects are highly speculative and uncertain.